Pros | Beats FD returns for both 3Y & 5Y duration. | Larger AUM within category. Beats FD returns for both 3Y & 5Y duration. | ||
Cons | 5Y returns in the bottom 25% of the category. 3Y returns in the bottom 25% of the category. | 3Y returns in the bottom 25% of the category. |
INDMoney rank | - | 7/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 6 Years | 12 Years | ||
Fund Size | 88 Cr | 8346 Cr | ||
Min Investment | SIP ₹200 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 1.22% | 0.91% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 30 | 41 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (10.39%) Apollo Hospitals Enterprise Ltd (5.9%) Cipla Ltd (5.35%) Torrent Pharmaceuticals Ltd (5.34%) Fortis Healthcare Ltd (4.92%) | Sun Pharmaceuticals Industries Ltd (12.67%) Divi's Laboratories Ltd (8.07%) Lupin Ltd (7.26%) Cipla Ltd (6.29%) Apollo Hospitals Enterprise Ltd (5.97%) | ||
No of Sectors | 2 | 1 | ||
Top 3 Sectors | Health (92.02%) Basic Materials (7.98%) | Health (100%) | ||
Equity % | 97.1% | 99.66% | ||
Debt % | - | - | ||
P/E | 43.8 | 36.22 | ||
P/B | 5.96 | 5.77 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 1.25% | 1.87% | ||
3-Month Return | 1.8% | 0.16% | ||
6-Month Return | 8.06% | 5.63% | ||
1-Year Return | 4.59% | 5.23% | ||
3-Year Return | 21.86% | 22.67% | ||
5-Year Return | 15.59% | 18.83% |
Sharpe | 0.89 | 0.96 | ||
Alpha | -1.24 | -0.21 | ||
Beta | 0.92 | 0.91 | ||
Standard Deviation | 15.61 | 15.25 | ||
Information Ratio | -0.66 | -0.48 |
Description | LIC MF Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Karan Doshi | Sailesh Raj Bhan,Lokesh Maru,Divya Sharma,Kinjal Desai |